Malecare will be holding a free teleconference this Tuesday, April 30 at 6.m.
I will be speaking with Dr. James Gulley who is the Deputy Chief of the Laboratory of Tumor Immunology and Biology at the National Cancer Institute and the Director of the Clinical Trials Group. He also serves as a Senior Investigator within the Medical Oncology Branch of NCI.
The teleconference will review the new treatments for metastatic, castration-resistant advanced prostate cancer as well as a comprehensive conversation about the immune therapies known as cancer vaccines. We will be discussing approved and unapproved immune treatments with an expanded conversation about the investigational treatment PROSTVAC, which our speaker has been involved in both the development and testing.
We will end the teleconference by having Dr. Gulley answer some of the questions that have been sent to me.
If you are interested in listening in on the conference you can dial in at: 800-920-7486. The conference number is: 8534374. We are starting promptly at
6 p.m.
Joel T Nowak, M.A., M.S.W.
The conference call is scheduled for 6pm, in what time zone?
Good question, sorry about that. It is scheduled for 6 p.m. Eastern Day Light Time. — Joel
Also, we will be recording the teleconference. We will make the recording available on-line as well as a written transcript. – Joel
Hi Joel,
When will the full transcript be available, and where will it be located to download?
Thanks much,
Pete
I would very much like to hear the recording of the April 29th teleconference. How can I access it?
Jim
I will make an announcment when it becomes available, it is currently being transcribed. – Joel
It will be posted soon, I will make an announcement as soon as it is available.- Joel
Not yet, We have been side tracked by the launching of Start A Cure, burt will get to it shortly. – Joel
Yes, the transcript and the recording of the session are posted at Malecare.org. Go to the page listed as teleconferece archive. I have to say when I listened back to the call I found it very informative. – Joel